{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T10:34:49Z","timestamp":1772361289825,"version":"3.50.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Res Methodol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Real-world evidence (RWE) plays a key role in regulatory and healthcare decision-making, but the potentially fragmentated nature of generated evidence may limit its utility for clinical decision-making. Heterogeneity and a lack of reproducibility in RWE resulting from inconsistent application of methodologies across data sources should be minimized through harmonization.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This paper\u2019s aim is to describe and reflect upon a multidisciplinary research platform (FOUNTAIN; <jats:bold>F<\/jats:bold>ineren<jats:bold>O<\/jats:bold>ne m<jats:bold>U<\/jats:bold>lti-database <jats:bold>N<\/jats:bold>e<jats:bold>T<\/jats:bold>work for evidence gener<jats:bold>A<\/jats:bold>t<jats:bold>I<\/jats:bold>o<jats:bold>N<\/jats:bold>) with coordinated studies using diverse RWE generation approaches and explore the platform\u2019s strengths and limitations. With guidance from an executive advisory committee of multidisciplinary experts and patient representatives, the goal of the FOUNTAIN platform is to harmonize RWE generation across a portfolio of research projects, including research partner collaborations and a common data model (CDM)\u2013based program. FOUNTAIN\u2019s overarching objectives as a research platform are to establish long-term collaborations among pharmacoepidemiology research partners and experts and to integrate diverse approaches for RWE generation, including global protocol execution by research partners in local data sources and common protocol execution in multiple data sources through federated data networks, while ensuring harmonization of medical definitions, methodology, and reproducible artifacts across all studies. Specifically, the aim of the multiple studies run within the frame of FOUNTAIN is to provide insight into the real-world utilization, effectiveness, and safety of finerenone across its life-cycle.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Currently, the FOUNTAIN platform includes 9 research partner collaborations and 8 CDM-mapped data sources from 7 countries (United States, United Kingdom, China, Japan, The Netherlands, Spain, and Denmark). These databases and research partners were selected after a feasibility fit-for-purpose evaluation. Six multicountry, multidatabase, cohort studies are ongoing to describe patient populations, current standard of care, comorbidity profiles, healthcare resource use, and treatment effectiveness and safety in different patient populations with chronic kidney disease and type 2 diabetes. Strengths and potential limitations of FOUNTAIN are described in the context of valid RWE generation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The establishment of the FOUNTAIN platform has allowed harmonized execution of multiple studies, promoting consistency both within individual studies that employ multiple data sources and across all studies run within the platform\u2019s framework. FOUNTAIN presents a proposal to efficiently improve the consistency and generalizability of RWE on finerenone.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12874-024-02344-w","type":"journal-article","created":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T13:02:17Z","timestamp":1727787737000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["FOUNTAIN: a modular research platform for integrated real-world evidence generation"],"prefix":"10.1186","volume":"24","author":[{"given":"Nikolaus G.","family":"Oberprieler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manel","family":"Pladevall-Vila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Johannes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Bradley","family":"Layton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asieh","family":"Golozar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Lavallee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangfang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Kubin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Vizcaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,1]]},"reference":[{"key":"2344_CR1","unstructured":"Transcelerate. RWD Initiative. 2024. https:\/\/www.transceleratebiopharmainc.com\/initiatives\/real-world-data\/. Accessed 21 Mar 2024."},{"key":"2344_CR2","unstructured":"Transcelerate. Real-world data solutions. 2024. https:\/\/www.transceleratebiopharmainc.com\/assets\/real-world-data-solutions\/#audit-readiness. Accessed 22 Mar 2024."},{"issue":"3","key":"2344_CR3","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.jval.2017.08.3013","volume":"21","author":"DC Malone","year":"2018","unstructured":"Malone DC, Brown M, Hurwitz JT, Peters L, Graff JS. Real-world evidence: useful in the real world of US payer decision making? How? When? And what studies? Value Health. 2018;21(3):326\u201333.","journal-title":"Value Health"},{"issue":"1","key":"2344_CR4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/cpt.2410","volume":"111","author":"K Nishioka","year":"2022","unstructured":"Nishioka K, Makimura T, Ishiguro A, Nonaka T, Yamaguchi M, Uyama Y. Evolving acceptance and use of RWE for regulatory decision making on the benefit\/risk assessment of a drug in Japan. Clin Pharmacol Ther. 2022;111(1):35\u201343.","journal-title":"Clin Pharmacol Ther"},{"issue":"18","key":"2344_CR5","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1056\/NEJMp2200089","volume":"386","author":"J Concato","year":"2022","unstructured":"Concato J, Corrigan-Curay J. Real-world evidence - where are we now? N Engl J Med. 2022;386(18):1680\u20132.","journal-title":"N Engl J Med"},{"issue":"4","key":"2344_CR6","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1136\/amiajnl-2014-002747","volume":"21","author":"RL Fleurence","year":"2014","unstructured":"Fleurence RL, Curtis LH, Califf RM, Platt R, Selby JV, Brown JS. Launching PCORnet, a national patient-centered clinical research network. J Am Med Inform Assoc. 2014;21(4):578\u201382.","journal-title":"J Am Med Inform Assoc"},{"key":"2344_CR7","unstructured":"Ray R, Locke T, Hendricks-Sturrup R. Aligning shared evidentiary needs among payers and regulators for a real-world data ecosystem. Duke-Margolis Center for Health Policy: 2022. https:\/\/healthpolicy.duke.edu\/publications\/aligning-shared-evidentiary-needs-among-payers-and-regulators-real-world-data. Accessed 19 Dec 2022."},{"key":"2344_CR8","unstructured":"European Health Data & Evidence Network. The European Health Data & Evidence Network portal. https:\/\/www.ehden.eu\/."},{"key":"2344_CR9","unstructured":"Brosch S, Eotvos O. DARWIN EU-Network of data, expertise and governance for medicines and public health purposes. ESMO public policy webinar: general data protection regulation and its impact on clinical research. 2021. https:\/\/www.esmo.org\/content\/download\/439775\/8425448\/1\/Sabine-Brosch-Orsolya-Eotvos-European-Medicines-Agency.pdf."},{"key":"2344_CR10","unstructured":"US Food and Drug Administration. Framework for FDA's real-world evidence program. 2018. https:\/\/www.fda.gov\/media\/120060\/download. Accessed 24 Dec 2022."},{"key":"2344_CR11","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jclinepi.2022.08.012","volume":"151","author":"SV Wang","year":"2022","unstructured":"Wang SV, Sreedhara SK, Bessette LG, Schneeweiss S. Understanding variation in the results of real-world evidence studies that seem to address the same question. J Clin Epidemiol. 2022;151:161\u201370.","journal-title":"J Clin Epidemiol"},{"key":"2344_CR12","unstructured":"McKinsey. Creating value from next-generation real-world evidence. July 2020. https:\/\/www.mckinsey.com\/industries\/life-sciences\/our-insights\/creating-value-from-next-generation-real-world-evidence#\/. Accessed 20 Mar 2024."},{"issue":"3","key":"2344_CR13","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","volume":"136","author":"M Kosiborod","year":"2017","unstructured":"Kosiborod M, Cavender MA, Fu AZ, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). Circulation. 2017;136(3):249\u201359.","journal-title":"Circulation"},{"issue":"23","key":"2344_CR14","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1016\/j.jacc.2018.03.009","volume":"71","author":"M Kosiborod","year":"2018","unstructured":"Kosiborod M, Lam CSP, Kohsaka S, et al. Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 Study. J Am Coll Cardiol. 2018;71(23):2628\u201339.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2344_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S2213-8587(19)30384-5","volume":"8","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Karasik A, Thuresson M, et al. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. Lancet Diabetes Endocrinol. 2020;8(1):27\u201335.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2344_CR16","unstructured":"Bristol Myers Squibb. Bristol-Myers Squibb-Pfizer Alliance ACROPOLIS\u2122 real-world data program grows to sample size of nearly one million lives worldwide. 20 August 2018. https:\/\/news.bms.com\/news\/corporate-financial\/2018\/Bristol-Myers-Squibb-Pfizer-Alliance-ACROPOLIS-Real-World-Data-Program-Grows-to-Sample-Size-of-Nearly-One-Million-Lives-Worldwide\/default.aspx. Accessed 20 Mar 2024."},{"issue":"1","key":"2344_CR17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/cpt.1426","volume":"106","author":"A Cave","year":"2019","unstructured":"Cave A, Kurz X, Arlett P. Real-world data for regulatory decision making: challenges and possible solutions for Europe. Clin Pharmacol Ther. 2019;106(1):36\u20139.","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"2344_CR18","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.jval.2020.04.002","volume":"23","author":"LS Orsini","year":"2020","unstructured":"Orsini LS, Berger M, Crown W, et al. Improving transparency to build trust in real-world secondary data studies for hypothesis testing-why, what, and how: recommendations and a road map from the Real-World Evidence Transparency Initiative. Value Health. 2020;23(9):1128\u201336.","journal-title":"Value Health"},{"issue":"1","key":"2344_CR19","doi-asserted-by":"publisher","first-page":"5126","DOI":"10.1038\/s41467-022-32310-3","volume":"13","author":"SV Wang","year":"2022","unstructured":"Wang SV, Sreedhara SK, Schneeweiss S. Reproducibility of real-world evidence studies using clinical practice data to inform regulatory and coverage decisions. Nat Commun. 2022;13(1):5126.","journal-title":"Nat Commun"},{"issue":"1","key":"2344_CR20","first-page":"1","volume":"15","author":"M Levenson","year":"2021","unstructured":"Levenson M, He W, Chen J, et al. Biostatistical considerations when using RWD and RWE in clinical studies for regulatory purposes: a landscape assessment. Stat Biopharm Res. 2021;15(1):1\u201320.","journal-title":"Stat Biopharm Res."},{"issue":"1","key":"2344_CR21","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/cpt.2466","volume":"111","author":"NM Gatto","year":"2022","unstructured":"Gatto NM, Campbell UB, Rubinstein E, et al. The structured process to identify fit-for-purpose data: a data feasibility assessment framework. Clin Pharmacol Ther. 2022;111(1):122\u201334.","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"2344_CR22","doi-asserted-by":"publisher","first-page":"711","DOI":"10.2217\/cer-2020-0228","volume":"10","author":"A Jaksa","year":"2021","unstructured":"Jaksa A, Wu J, Jonsson P, Eichler HG, Vititoe S, Gatto NM. Organized structure of real-world evidence best practices: moving from fragmented recommendations to comprehensive guidance. J Comp Eff Res. 2021;10(9):711\u201331.","journal-title":"J Comp Eff Res"},{"key":"2344_CR23","unstructured":"EMA. Real-world evidence framework to support EU regulatory decision-making: EMA\/289699\/2023. 2023. https:\/\/www.ema.europa.eu\/system\/files\/documents\/report\/real-world-evidence-framework-support-eu-regulatory-decision-making-report-experience-gained_en.pdf. Accessed 3 June 2024."},{"key":"2344_CR24","unstructured":"NICE. NICE real-world evidence framework: ECD9. 23 June 2022. https:\/\/www.nice.org.uk\/corporate\/ecd9\/chapter\/overview. Accessed 3 June 2024."},{"key":"2344_CR25","unstructured":"EMA. ICH M14 Guideline on general principles on plan, design and analysis of pharmacoepidemiological studies that utilize real-world data for safety assessment of medicines. 2024. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-m14-guideline-general-principles-plan-design-analysis-pharmacoepidemiological-studies-utilize-real-world-data-safety-assessment-medicines-step-2b_en.pdf. Accessed 14 June 2024."},{"key":"2344_CR26","unstructured":"International Council on Harmonization. ICH reflection paper: strategic approach to international harmonization of technical scientific requirements for pharmacoepidemiological studies submitted to regulatory agencies to advance more effective utilization of real-world data, 2019. 5 June 2019. https:\/\/admin.ich.org\/sites\/default\/files\/2019-08\/ICH_ReflectionPaper_Pharmacoepidemiology_2019_0605.pdf. Accessed 21 Mar 2024."},{"issue":"10","key":"2344_CR27","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1016\/j.jval.2022.09.001","volume":"25","author":"SV Wang","year":"2022","unstructured":"Wang SV, Potteg\u00e5rd A, Crown W, et al. HARmonized Protocol Template to Enhance Reproducibility of hypothesis evaluating real-world evidence studies on treatment effects: a good practices report of a joint ISPE\/ISPOR task force. Value Health. 2022;25(10):1663\u201372.","journal-title":"Value Health"},{"issue":"1","key":"2344_CR28","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jval.2022.04.1738","volume":"26","author":"EM Oehrlein","year":"2023","unstructured":"Oehrlein EM, Schoch S, Burcu M, et al. Developing patient-centered real-world evidence: emerging methods recommendations from a consensus process. Value Health. 2023;26(1):28\u201338.","journal-title":"Value Health"},{"key":"2344_CR29","doi-asserted-by":"publisher","first-page":"1289365","DOI":"10.3389\/fphar.2023.1289365","volume":"14","author":"R Claire","year":"2024","unstructured":"Claire R, Elvidge J, Hanif S, et al. Advancing the use of real world evidence in health technology assessment: insights from a multi-stakeholder workshop. Front Pharmacol. 2024;14:1289365.","journal-title":"Front Pharmacol"},{"key":"2344_CR30","first-page":"1","volume":"3","author":"KM Facey","year":"2020","unstructured":"Facey KM, Rannanheimo P, Batchelor L, Borchardt M, de Cock J. Real-world evidence to support Payer\/HTA decisions about highly innovative technologies in the EU-actions for stakeholders. Int J Technol Assess Health Care. 2020;3:1\u201310.","journal-title":"Int J Technol Assess Health Care"},{"issue":"4","key":"2344_CR31","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1002\/cpt.1577","volume":"107","author":"S Schneeweiss","year":"2020","unstructured":"Schneeweiss S, Brown JS, Bate A, Trifiro G, Bartels DB. Choosing among common data models for real-world data analyses fit for making decisions about the effectiveness of medical products. Clin Pharmacol Ther. 2020;107(4):827\u201333.","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"2344_CR32","doi-asserted-by":"publisher","first-page":"e230076","DOI":"10.57264\/cer-2023-0076","volume":"12","author":"D Vizcaya","year":"2023","unstructured":"Vizcaya D, Kovesdy CP, Reyes A, et al. Characteristics of patients with chronic kidney disease and type 2 diabetes initiating finerenone in the USA: a multi-database, cross-sectional study. J Comp Eff Res. 2023;12(8):e230076.","journal-title":"J Comp Eff Res"},{"issue":"1","key":"2344_CR33","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/cpt.1480","volume":"106","author":"NM Gatto","year":"2019","unstructured":"Gatto NM, Reynolds RF, Campbell UB. A structured preapproval and postapproval comparative study design framework to generate valid and transparent real-world evidence for regulatory decisions. Clin Pharmacol Ther. 2019;106(1):103\u201315.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"2344_CR34","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/s12874-022-01768-6","volume":"22","author":"F Liu","year":"2022","unstructured":"Liu F, Demosthenes P. Real-world data: a brief review of the methods, applications, challenges and opportunities. BMC Med Res Methodol. 2022;22(1):287.","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"2344_CR35","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/cpt.2479","volume":"111","author":"P Arlett","year":"2022","unstructured":"Arlett P, Kjaer J, Broich K, Cooke E. Real-world evidence in EU medicines regulation: enabling use and establishing value. Clin Pharmacol Ther. 2022;111(1):21\u20133.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"2344_CR36","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1177\/1932296819832661","volume":"14","author":"DC Klonoff","year":"2020","unstructured":"Klonoff DC. The new FDA real-world evidence program to support development of drugs and biologics. J Diabetes Sci Technol. 2020;14(2):345\u20139.","journal-title":"J Diabetes Sci Technol"},{"issue":"12","key":"2344_CR37","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1080\/13696998.2020.1840113","volume":"23","author":"SD Ramsey","year":"2020","unstructured":"Ramsey SD, Adamson BJ, Wang X, et al. Using electronic health record data to identify comparator populations for comparative effectiveness research. J Med Econ. 2020;23(12):1618\u201322.","journal-title":"J Med Econ"},{"issue":"5","key":"2344_CR38","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1210\/endrev\/bnab007","volume":"42","author":"S Schneeweiss","year":"2021","unstructured":"Schneeweiss S, Patorno E. Conducting real-world evidence studies on the clinical outcomes of diabetes treatments. Endocr Rev. 2021;42(5):658\u201390.","journal-title":"Endocr Rev"},{"issue":"372","key":"2344_CR39","doi-asserted-by":"publisher","first-page":"m4856","DOI":"10.1136\/bmj.m4856","volume":"12","author":"SV Wang","year":"2021","unstructured":"Wang SV, Pinheiro S, Hua W, et al. STaRT-RWE: structured template for planning and reporting on the implementation of real world evidence studies. BMJ. 2021;12(372):m4856.","journal-title":"BMJ"},{"issue":"2","key":"2344_CR40","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/cpt.946","volume":"103","author":"RA Miksad","year":"2018","unstructured":"Miksad RA, Abernethy AP. Harnessing the power of real-world evidence (RWE): a checklist to ensure regulatory-grade data quality. Clin Pharmacol Ther. 2018;103(2):202\u20135.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"2344_CR41","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2217\/cer-2016-0070","volume":"6","author":"R White","year":"2017","unstructured":"White R. Building trust in real-world evidence and comparative effectiveness research: the need for transparency. J Comp Eff Res. 2017;6(1):5\u20137.","journal-title":"J Comp Eff Res"},{"issue":"1","key":"2344_CR42","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2217\/cer-2017-0073","volume":"7","author":"MS Olson","year":"2018","unstructured":"Olson MS. Developing an integrated strategy for evidence generation. J Comp Eff Res. 2018;7(1):5\u20139.","journal-title":"J Comp Eff Res"},{"issue":"1","key":"2344_CR43","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.1038\/s41467-020-18849-z","volume":"11","author":"E Burn","year":"2020","unstructured":"Burn E, You SC, Sena AG, et al. Deep phenotyping of 34,128 adult patients hospitalised with COVID-19 in an international network study. Nat Commun. 2020;11(1):5009.","journal-title":"Nat Commun"},{"key":"2344_CR44","unstructured":"OHDSI. The Book of OHDSI: Observational Health Data Sciences and Informatics. OHDSI; 2021. https:\/\/ohdsi.github.io\/TheBookOfOhdsi\/."},{"key":"2344_CR45","unstructured":"Foundation for the National Institutes of Health. Observational Medical Outcomes Partnership (OMOP). https:\/\/fnih.org\/what-we-do\/major-completed-programs\/observational-medical-outcomes-partnership-omop."},{"issue":"1","key":"2344_CR46","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.1017\/S0266462322000605","volume":"38","author":"G Capkun","year":"2022","unstructured":"Capkun G, Corry S, Dowling O, et al. Can we use existing guidance to support the development of robust real-world evidence for health technology assessment\/payer decision-making? Int J Technol Assess Health Care. 2022;38(1):e79.","journal-title":"Int J Technol Assess Health Care"},{"key":"2344_CR47","unstructured":"OHDSI. OHDSI - Observational Health Data Sciences and Informatics. https:\/\/www.ohdsi.org\/."},{"key":"2344_CR48","unstructured":"OHDSI. OHDSI - software tools. https:\/\/www.ohdsi.org\/software-tools\/."},{"key":"2344_CR49","unstructured":"Albert Einstein College of Medicine. ATLAS: new research platform for health data. https:\/\/www.einsteinmed.edu\/centers\/ictr\/health-data-innovations\/atlas\/."},{"key":"2344_CR50","unstructured":"Rao G. ATLAS - CohortDiagnostics. 13 November 2021. https:\/\/ohdsi.github.io\/CohortDiagnostics\/articles\/CohortDiagnosticsUsingWebApi.html. Accessed 24 Dec 2022."},{"key":"2344_CR51","first-page":"966","volume":"310","author":"M Schuemie","year":"2024","unstructured":"Schuemie M, Reps J, Black A, et al. Health-Analytics Data to Evidence Suite (HADES): open-source software for observational research. Stud Health Technol Inform. 2024;310:966\u201370.","journal-title":"Stud Health Technol Inform."},{"key":"2344_CR52","unstructured":"National Institutes of Health. An observational study, called FINEGUST, to learn more about how people with chronic kidney disease and type 2 diabetes are treated and how the introduction of new treatment options, like finerenone, impacts clinical practice (FINEGUST): NCT05526157.ClinicalTrialsgov. NIH U.S. National Library of Medicine; 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05526157?term=NCT05526157&draw=2&rank=1. Accessed 9 Feb 2023."},{"key":"2344_CR53","unstructured":"National Institutes of Health. An observational study called FIRST-2.0 to learn more about the use of the study treatment finerenone including how safe it is and how well it works under real-world conditions (FIRST-2): NCT05703880. ClinicalTrialsgov. NIH U.S. National Library of Medicine; 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05703880?term=NCT05703880&draw=2&rank=1. Accessed 9 Feb 2023."},{"key":"2344_CR54","unstructured":"National Institutes of Health. An observational study called FINEROD to learn more about the use of the treatment finerenone including how safe it is and how well it works under real-world conditions (FINEROD). NCT06278207. ClinicalTrialsgov. NIH U.S. National Library of Medicine; 2024. \nhttps:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT06278207."},{"issue":"S1","key":"2344_CR55","first-page":"243","volume":"35","author":"NG Oberprieler","year":"2023","unstructured":"Oberprieler NG, Pladevall-Vila M, Johannes CB, et al. FOUNTAIN: a modular research platform for integrated real-world evidence generation. Pharmacoepidemiol Drug Saf. 2023;35(S1):243.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2344_CR56","unstructured":"EMA. FINErenone druG Utilization Study and assessment of Temporal changes following availability of different treatment options in patients with chronic kidney disease and type 2 diabetes (FINEGUST). 22 Aug 2022. https:\/\/catalogues.ema.europa.eu\/node\/3399\/methodological-aspects. Accessed 3 June 2024."},{"issue":"S1","key":"2344_CR57","first-page":"235","volume":"32","author":"M Lavallee","year":"2023","unstructured":"Lavallee M, Vizcaya D, Oberprieler NG, James G, Golozar A. Treatment with antidiabetics in patients with T2D andmoderate to severe CKD: A multi-database FOUNTAIN analysis. Pharmacoepidemiol Drug Saf. 2023;32(S1):235.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2344_CR58","doi-asserted-by":"crossref","unstructured":"Oberprieler NG, Kovesdy CP, Layton JB, et al. Early use and effectiveness of finerenone in US patients with CKD and type 2 diabetes: a FOUNTAIN platform analysis. Poster presented at Kidney Week. Philadelphia; 2023.","DOI":"10.1681\/ASN.20233411S1856c"},{"key":"2344_CR59","unstructured":"GitHub HADES. Health analytics data-to-evidence suite. 2020. https:\/\/github.com\/OHDSI\/Hades."},{"key":"2344_CR60","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3389\/fphar.2018.00435","volume":"9","author":"A Pacaci","year":"2018","unstructured":"Pacaci A, Gonul S, Sinaci AA, Yuksel M, Laleci Erturkmen GB. A semantic transformation methodology for the secondary use of observational healthcare data in postmarketing safety studies. Front Pharmacol. 2018;9:435.","journal-title":"Front Pharmacol"},{"issue":"3","key":"2344_CR61","doi-asserted-by":"publisher","first-page":"ooab001","DOI":"10.1093\/jamiaopen\/ooab001","volume":"4","author":"V Papez","year":"2021","unstructured":"Papez V, Moinat M, Payralbe S, et al. Transforming and evaluating electronic health record disease phenotyping algorithms using the OMOP common data model: a case study in heart failure. JAMIA Open. 2021;4(3):ooab001.","journal-title":"JAMIA Open."},{"key":"2344_CR62","doi-asserted-by":"publisher","first-page":"104925","DOI":"10.1016\/j.ijmedinf.2022.104925","volume":"169","author":"Y Peng","year":"2023","unstructured":"Peng Y, Henke E, Reinecke I, Zoch M, Sedlmayr M, Bathelt F. An ETL-process design for data harmonization to participate in international research with German real-world data based on FHIR and OMOP CDM. Int J Med Inform. 2023;169:104925.","journal-title":"Int J Med Inform"},{"key":"2344_CR63","doi-asserted-by":"publisher","first-page":"104002","DOI":"10.1016\/j.jbi.2022.104002","volume":"127","author":"Y Yu","year":"2022","unstructured":"Yu Y, Zong N, Wen A, et al. Developing an ETL tool for converting the PCORnet CDM into the OMOP CDM to facilitate the COVID-19 data integration. J Biomed Inform. 2022;127:104002.","journal-title":"J Biomed Inform"},{"issue":"1","key":"2344_CR64","first-page":"1110","volume":"2","author":"R Makadia","year":"2014","unstructured":"Makadia R, Ryan PB. Transforming the premier perspective hospital database into the Observational Medical Outcomes Partnership (OMOP) common data model. EGEMS (Wash DC). 2014;2(1):1110.","journal-title":"EGEMS (Wash DC)"}],"container-title":["BMC Medical Research Methodology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12874-024-02344-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12874-024-02344-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12874-024-02344-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T13:03:07Z","timestamp":1727787787000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedresmethodol.biomedcentral.com\/articles\/10.1186\/s12874-024-02344-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2344"],"URL":"https:\/\/doi.org\/10.1186\/s12874-024-02344-w","relation":{},"ISSN":["1471-2288"],"issn-type":[{"value":"1471-2288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,1]]},"assertion":[{"value":"24 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"NGO, FL, MK, and DV are employees of Bayer AG, the sponsor of the FOUNTAIN program. MPV, CJ, and BL are employees of RTI Health Solutions, an independent nonprofit research organization that has received research funding for components of the FOUNTAIN program. AG and ML are employees of Odysseus, Inc., which has received research funding for components of the FOUNTAIN program.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"224"}}